Tudor Investment Corp ET AL Purchases 77,464 Shares of Hinge Health Inc. $HNGE

Tudor Investment Corp ET AL grew its position in Hinge Health Inc. (NYSE:HNGE) by 25.9% in the third quarter, HoldingsChannel.com reports. The fund owned 376,266 shares of the company’s stock after buying an additional 77,464 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Hinge Health were worth $18,467,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Hinge Health during the 2nd quarter valued at $43,840,000. Seven Grand Managers LLC acquired a new position in Hinge Health during the 2nd quarter worth about $12,938,000. Foresite Capital Management VI LLC bought a new stake in Hinge Health during the 2nd quarter worth about $6,986,000. Ensign Peak Advisors Inc bought a new stake in Hinge Health during the 2nd quarter worth about $16,172,000. Finally, Franklin Resources Inc. acquired a new stake in Hinge Health in the 2nd quarter valued at about $28,462,000.

Hinge Health Price Performance

Shares of NYSE HNGE opened at $42.50 on Friday. Hinge Health Inc. has a fifty-two week low of $30.08 and a fifty-two week high of $62.18. The firm has a market capitalization of $3.35 billion and a P/E ratio of -3.32. The company’s 50 day simple moving average is $41.10 and its 200 day simple moving average is $46.79.

Hinge Health (NYSE:HNGE) last issued its earnings results on Tuesday, February 10th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.04 by $0.45. The business had revenue of $170.73 million for the quarter, compared to the consensus estimate of $157.31 million. The company’s revenue for the quarter was up 45.5% on a year-over-year basis.

Insider Buying and Selling

In other news, CEO Daniel Antonio Perez sold 166,665 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $40.26, for a total transaction of $6,709,932.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Budge sold 10,491 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $48.41, for a total value of $507,869.31. Following the completion of the sale, the chief financial officer directly owned 441,174 shares of the company’s stock, valued at approximately $21,357,233.34. This trade represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 525,487 shares of company stock worth $23,227,028.

Analysts Set New Price Targets

HNGE has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Hinge Health in a research report on Thursday, January 22nd. Barclays decreased their price objective on Hinge Health from $60.00 to $52.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 11th. Needham & Company LLC restated a “buy” rating and set a $59.00 target price on shares of Hinge Health in a research report on Wednesday, February 11th. Wells Fargo & Company initiated coverage on Hinge Health in a research note on Thursday, January 8th. They set an “overweight” rating and a $68.00 price target on the stock. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $65.00 price target on shares of Hinge Health in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.07.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.